Pionyr Immunotherapeutics competitors

Specialties:Executive Management, Strategic Transactions, Biotech-Pharma Business Development, Strategic Patent Counseling and IP Monetization, Oncology, Immunology, Immuno-oncology, translational pharmacology and drug development

Thayer White is a CEO & CSO at GO Therapeutics. He has worked as Dir Biochen at CTI BIOPHARMA CORP. Thayer studied at University of Washington between 1977 and 1993.

Norrie J. W. Russell is a CEO at Siamab Therapeutics, Inc..

Dr. Hughes has over 25 years of experience in pharmaceutical research and development. Dr. Hughes joined Zafgen in 2008 as president, chief executive officer and a member of the company’s board of directors. From 1987 to 2008, Dr. Hughes held several positions at Novartis AG (and formerly Sandoz Pharmaceuticals) including vice president and global head of the cardiovascular and metabolic diseases therapeutic area at the Novartis Institutes for BioMedical Research in Cambridge, MA. In these roles he oversaw many drug discovery and development projects targeting obesity, diabetes, and heart disease. As a scientist, Dr. Hughes led Novartis’ efforts to discover and develop its dipeptidylpeptidase IV inhibitor vildagliptin (Galvus®/Eucreas®), a drug used for the treatment of type 2 diabetes, currently approved in 70 countries. Dr. Hughes is the author of over 40 peer-reviewed publications and is an inventor on numerous issued and pending patents related to the treatment of diabetes, cardiovascular disease, and obesity. Dr. Hughes also serves as a director on the board of Miragen Therapeutics, Inc., and is a member of several scientific and strategic advisory boards, including Broadview Ventures and Nimbus Discovery, LLC.

Jan Skvarka is a Board Member at TRILLIUM THERAPEUTICS INC and President/CEO at TRILLIUM THERAPEUTICS INC and is based in Cambridge, Massachusetts. He has worked as President/CEO at Tal Medical Inc, Partner at Bain & Company, and Manager at Pricewaterhouse Coopers (PwC). Jan attended Harvard Business School between 1998 and 1999 and University of Economics, Bratislava, Slovakia.

Dr. Lara S. Sullivan is the Chief Executive Officer of Pyxis Oncology. Prior to joining Pyxis, Lara was Founder and President of SpringWorks Therapeutics (NASDAQ: SWTX), a clinical stage biopharmaceutical company spun-out from Pfizer. While at Pfizer, Lara led strategy, competitive intelligence and portfolio operations for the company’s early-stage R&D pipeline. Prior to joining Pfizer, Lara was an associate partner at McKinsey & Company, where she specialized in biopharmaceutical R&D productivity and efficiency. Lara also served as a principal at Paul Capital Partners, where she led due diligence for healthcare investments, and earlier in her career worked in healthcare equity research and healthcare municipal finance at Credit Suisse First Boston. Lara holds an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from The Wharton School at the University of Pennsylvania, and a B.A. in Comparative Literature from Cornell University.